124 related articles for article (PubMed ID: 31751393)
1. A model-based framework for chronic hepatitis C prevalence estimation.
Hamadeh A; Feng Z; Krahn M; Wong WWL
PLoS One; 2019; 14(11):e0225366. PubMed ID: 31751393
[TBL] [Abstract][Full Text] [Related]
2. Impact of new direct-acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection.
Forouzannia F; Hamadeh A; Passos-Castilho AM; Erman A; Yu A; Feng Z; Janjua NZ; Sander B; Greenaway C; Wong WWL
Liver Int; 2024 Jun; 44(6):1383-1395. PubMed ID: 38445848
[TBL] [Abstract][Full Text] [Related]
3. Disease burden of chronic hepatitis C among immigrants in Canada.
Chen W; Krahn M
J Viral Hepat; 2015 Dec; 22(12):1043-54. PubMed ID: 26110922
[TBL] [Abstract][Full Text] [Related]
4. Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada, using population-based cohort studies.
Hamadeh A; Haines A; Feng Z; Thein HH; Janjua NZ; Krahn M; Wong WWL
J Viral Hepat; 2020 Dec; 27(12):1419-1429. PubMed ID: 32810886
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C--an update.
Holmes J; Thompson A; Bell S
Aust Fam Physician; 2013 Jul; 42(7):452-6. PubMed ID: 23826595
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C prevalence in Denmark in 2016-An updated estimate using multiple national registers.
Nielsen S; Hansen JF; Hay G; Cowan S; Jepsen P; Omland LH; Krarup HB; Søholm J; Lazarus JV; Weis N; Øvrehus A; Christensen PB
PLoS One; 2020; 15(9):e0238203. PubMed ID: 32881877
[TBL] [Abstract][Full Text] [Related]
7. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden.
Büsch K; Waldenström J; Lagging M; Aleman S; Weiland O; Kövamees J; Duberg AS; Söderholm J
Scand J Gastroenterol; 2017 Jan; 52(1):61-68. PubMed ID: 27598393
[TBL] [Abstract][Full Text] [Related]
9. HCV Ag quantification as a one-step procedure in diagnosing chronic hepatitis C infection in Cameroon: the ANRS 12336 study.
Duchesne L; Njouom R; Lissock F; Tamko-Mella GF; Rallier S; Poiteau L; Soulier A; Chevaliez S; Vernet G; Rouveau N; Pawlotsky JM; Girard PM; Lacombe K
J Int AIDS Soc; 2017 May; 20(1):21446. PubMed ID: 28530032
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of transfusion-acquired hepatitis C in an Australian bleeding disorders population.
Northcott MJ; Ong WL; Walsh M; McCarthy P; Belleli D; Tran H; Street A; Kemp W; Davis AK
Haemophilia; 2013 Nov; 19(6):847-52. PubMed ID: 23738855
[TBL] [Abstract][Full Text] [Related]
11. Estimating the scale of chronic hepatitis C virus infection in the EU/EEA: a focus on migrants from anti-HCV endemic countries.
Falla AM; Ahmad AA; Duffell E; Noori T; Veldhuijzen IK
BMC Infect Dis; 2018 Jan; 18(1):42. PubMed ID: 29338702
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
[TBL] [Abstract][Full Text] [Related]
13. HCV and HBV prevalence based on home blood self-sampling and screening history in the general population in 2016: contribution to the new French screening strategy.
Brouard C; Saboni L; Gautier A; Chevaliez S; Rahib D; Richard JB; Barin F; Larsen C; Sommen C; Pillonel J; Delarocque-Astagneau E; Lydié N; Lot F;
BMC Infect Dis; 2019 Oct; 19(1):896. PubMed ID: 31660879
[TBL] [Abstract][Full Text] [Related]
14. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
[TBL] [Abstract][Full Text] [Related]
15. Assessment of hepatic fibrosis by fibroscan in egyptian chronic hemodialysis patients with chronic Hepatitis C (genotype 4): A single-center study.
Zayed BEM; Elsharkawy A; Abdou M; Abd Al Fatah DS; El-Shabony TH
Saudi J Kidney Dis Transpl; 2017; 28(4):764-773. PubMed ID: 28748878
[TBL] [Abstract][Full Text] [Related]
16. The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
Zheng YX; Zhou PC; Zhou RR; Fan XG
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):759-766. PubMed ID: 28240613
[TBL] [Abstract][Full Text] [Related]
17. Current status of liver disease in Korea: hepatitis C.
Lim YS
Korean J Hepatol; 2009 Dec; 15 Suppl 6():S25-8. PubMed ID: 20037276
[TBL] [Abstract][Full Text] [Related]
18. The impact of hepatitis C virus outside the liver: Evidence from Asia.
Younossi ZM; Tanaka A; Eguchi Y; Lim YS; Yu ML; Kawada N; Dan YY; Brooks-Rooney C; Negro F; Mondelli MU
Liver Int; 2017 Feb; 37(2):159-172. PubMed ID: 27748564
[TBL] [Abstract][Full Text] [Related]
19. Estimation of COVID-19 Period Prevalence and the Undiagnosed Population in Canadian Provinces: Model-Based Analysis.
Hamadeh A; Feng Z; Niergarth J; Wong WW
JMIR Public Health Surveill; 2021 Sep; 7(9):e26409. PubMed ID: 34228626
[TBL] [Abstract][Full Text] [Related]
20. Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
Guo P; Li G; Sun X; Wu D
Infect Genet Evol; 2016 Nov; 45():48-55. PubMed ID: 27543394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
